8F8FResponsible DepartmentDepartment of Advanced Molecular TherapyResearch PartnerPeriotherapia Co.,Ltd.Responsible DepartmentDepartment of Frontier Research in Tumor ImmunologyResearch PartnerShionogi & Co., Ltd.222208010802"Alternative splicing variant (ASV)," a mechanism in which multiple products are produced from a single gene by variant switch, not only enables the acquisition of complex morphology and cellular functions of multicellular organisms but is also deeply involved in the pathogenesis of several diseases.The purpose of this research is to selectively inhibit only ASV that is involved in the pathogenesis of chronic diseases such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy without inhibiting physiological ASV. We think that a safe and efficient therapy can be provided by selective inhibition of ASV. In this course, we will analyze the molecular mechanisms of pathological and physiological periostin and its in vivo functions such as transport of periostin mutants via exosomes or not.Immunotherapy for cancers is expected to become an additional choice for cancer treatment. The therapy, however, does not necessarily provide successful results because of its anti-tumor effect prevention by immune suppressive cells, including regulatory T cells. Therefore, we first have to examine the molecular mechanisms by which cancer cells escape from immune surveillance, and identify molecules that clearly distinguish regulatory T cells from effector T cells. These molecules would be expected to be applicable for regulatory T cell-depletion in cancer patients, leading to the enhancement of anti-tumor activity.A-28A-5TANIYAMA YoshiakiSpecially Appointed ProfessorDepartment of Advanced Molecular TherapyOHKURA NaganariSpecially Appointed ProfessorDepartment of Frontier Research in Tumor ImmunologyAnalysis of the functions of pathological or physiological periostinThe development of immunotherapy targeting immune suppressive molecules and cells
元のページ ../index.html#23